Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid intravenous ferric carboxymaltose for iron deficiency anaemia
ACTRN12612000653864Phase 2Not yet recruiting
- Sponsor
- Monash Medical Centre
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (3 arms), sponsored by Monash Medical Centre. Primary endpoint: Infusion-related safety of rapid dose undiluted intravenous injection of ferric carboxymaltose administered over 1 minute. Planned start Aug 2012; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12612000653864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000653864.